

Travax® Content Changes Sample

Travax Content Changes – Feb. 1, 2018

Shoreland's *Travax Content Changes*

Afghanistan, South Africa: Malaria Information

The malaria maps and text for Afghanistan and South Africa have undergone substantive revisions.

Library Update: Guidelines for Shingrix Use

The Library article [Herpes Zoster](#) has been updated with the final detailed CDC recommendations for Shingrix (zoster vaccine recombinant, adjuvanted; GSK).

Key Points:

- Shingrix is recommended preferentially over Zostavax (zoster vaccine live attenuated; Merck) in immunocompetent persons aged ≥ 50 years.
- Vaccination with a full 2-dose series of Shingrix is recommended for those previously vaccinated with Zostavax.
- Shingrix is recommended for use in persons taking low-dose immunosuppressive therapy (e.g., < 20 mg/day of prednisone or equivalent or using inhaled or topical steroids) and persons anticipating immunosuppression or who have recovered from an immunocompromising illness.
- Recommendations for Shingrix use in immunocompromised persons and those on moderate to high doses of immunosuppressive therapy are not available.
- Shingrix should not be administered during an acute episode of herpes zoster but can be administered as soon as symptoms resolve.

© 2018 Shoreland, Inc. All rights reserved.

Travax Content Changes notifies subscribers of key changes that have recently been made in Travax content. Typically the items pertain to *Destinations* and *Library* and include malaria, travel immunizations, and *Library* topic changes. A list of additional weekly changes is available on the Travax *What's New* page. Travax content represents decision-relevant, expert synthesis of real-time data reconciled with new and existing available advice from authoritative national and international bodies.